

Rachelle S. Doody, M.D., Ph.D.



- **Distinguished Emeritus Professor of Neurology**
Baylor College of Medicine
- **Effie Marie Cain Chair in Alzheimer's Disease Research**
Baylor College of Medicine
- **Director, Alzheimer's Disease and Memory Disorders Center**
Baylor College of Medicine
- **Program Director, Alzheimer's Disease and Dementia Fellowship**
Baylor College of Medicine

CONTACT INFORMATION

Rachelle S. Doody, M.D., Ph.D.
Baylor Neurology
Baylor College of Medicine Medical Center, McNair Campus
7200 Cambridge St., 9th Floor, MS: BCM609
Houston, Texas 77030

Fax: 713-798-5326
Email: rdoody@bcm.edu

SPECIALITY

- Alzheimer's Disease
- Memory Disorders

CERTIFICATION

- American Board of Psychiatry and Neurology, Neurology

EDUCATION

- M.D./Ph.D., Baylor College of Medicine, Houston, Texas
- Internship, Internal Medicine, McGill University Faculty of Medicine, Montreal, QC, Canada
- Residency, Neurology, Baylor College of Medicine, Houston, Texas

WEBSITE

- Alzheimer's Disease and Memory Disorders Center
(<https://www.bcm.edu/healthcare/care-centers/alzheimers>)

CLINIC APPOINTMENTS

713-798-4734

CONSULT

713-798-4734

CLINIC LOCATION

Baylor Neurology
Baylor College of Medicine Medical Center, McNair Campus

7200 Cambridge St., 9th Floor, MS: BCM609
Houston, Texas 77030

CLINICAL INTERESTS

Alzheimer's disease, neurodegenerative dementias, ischemic vascular dementia, memory loss, mild cognitive impairment

RESEARCH INTERESTS

- Cognitive aspects of Alzheimer's disease, dementia, and aphasia
- Alzheimer's Disease therapeutics and modeling of progression for clinical prognostication, validation of biological markers, and enhancing design of AD clinical trials

BCM HONORS

- Distinguished faculty, 2011.

HONORS & AWARDS

- Listed annually in Best Doctors in America, Central Region, 1996-present.
- Distinguished alumni, Rice University, Houston, TX, 2009.
- Houston Healthcare Heroes, 2009.
- Zenith Award National Alzheimer's Association, 2002.

GRANTS (NIH FUNDING)

- Doody RS (Principal Investigator). Alzheimers Disease Research Center. National Institute on Aging P50 grant; \$937,599 awarded in direct costs, Sept. 29, 1989–May 31, 2004.

JOURNAL PUBLICATIONS

1. Ostrowitzki S, Bittner T, Sink KM, Mackey H, Rabe C, Honig LS, et al. Evaluating the safety and efficacy of crenezumab vs placebo in adults with early Alzheimer disease: Two phase 3 randomized placebo-controlled trials. *JAMA Neurol.* 2022;79(11):1113-21. PMID: 36121669.
2. Pavlik VN, Burnham SC, Kass JS, Helmer C, Palmqvist S, Vassilaki M, et al. Connecting Cohorts to Diminish Alzheimer's Disease (CONCORD-AD): A report of an international research collaboration network. *J Alzheimers Dis.* 2022;85(1):31-45. PMID: 34776434.
3. Fu X, Yu W, Ke M, Wang X, Zhang J, Luo T, et al. Chinese version of the Baylor Profound Mental Status Examination: A brief staging measure for patients with severe Alzheimer's disease. *J Prev Alzheimers Dis.* 2021;8(2):175-80. PMID: 33569564.
4. Sood A, Pavlik V, Darby E, Chan W, Doody R. Different cognitive profiles are associated with progression rate and age at death in probable Alzheimer's disease. *J Alzheimers Dis.* 2021;80(2):735-47. PMID: 33579838.
5. Balsis S, Geraci L, Bengtson J, Lowe DA, Choudhury TK, Tirso R, et al. Statistical model of dynamic markers of the Alzheimer's pathological cascade. *J Gerontol B Psychol Sci Soc Sci.* 2018;73(6):964-73. PMID: 29741663.
6. Jia J, Wei C, Jia L, Tang Y, Liang J, Zhou A, et al. Efficacy and safety of donepezil in Chinese patients with severe Alzheimer's disease: A randomized controlled trial. *J Alzheimers Dis.* 2017;56(4):1495-504. PMID: 28157100.
7. Li K, Chan W, Doody RS, Quinn J, Luo S, Alzheimer's Disease Neuroimaging Initiative. Prediction of conversion to Alzheimer's disease with longitudinal measures and time-to-event data. *J Alzheimers Dis.* 2017;58(2):361-71. PMID: 28436391.
8. Nave S, Doody RS, Boada M, Grimmer T, Savola JM, Delmar P, et al. Sembragiline in moderate Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled phase ii trial (MAYFLOWER RoAD). *J Alzheimers Dis.* 2017;58(4):1217-28. PMID: 28550255.
9. Woodward MR, Amrutkar CV, Shah HC, Benedict RH, Rajakrishnan S, Doody RS, et al. Validation of olfactory deficit as a biomarker of Alzheimer disease. *Neurol Clin Pract.* 2017;7(1):5-14. PMID: 28243501.
10. Alverson WA, Massman PJ, Doody RS. Prevalence and correlates of cognitive asymmetry in a large sample of Alzheimer's disease patients. *J Clin Exp Neuropsychol.* 2016;38(5):516-26. PMID: 26757777.
11. Bang J, Lobach IV, Lang AE, Grossman M, Knopman DS, Miller BL, et al. Predicting disease progression in progressive supranuclear palsy in multicenter clinical trials. *Parkinsonism Relat Disord.* 2016;28:41-8. PMID: 27172829.

12. Benoit JS, Chan W, Luo S, Yeh HW, Doody R. A hidden Markov model approach to analyze longitudinal ternary outcomes when some observed states are possibly misclassified. *Stat Med*. 2016;35(9):1549-57. PMID: 26782946.
13. Doody RS, D'Amico S, Cutler AJ, Davis CS, Shin P, Ledon F, et al. An open-label study to assess safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in dementia: PRISM II results. *CNS Spectr*. 2016;21(6):450-9. PMID: 26471212.
14. Gordon MF, Lenderking WR, Duhig A, Chandler J, Lundy JJ, Miller DS, et al. Development of a patient-reported outcome instrument to assess complex activities of daily living and interpersonal functioning in persons with mild cognitive impairment: The qualitative research phase. *Alzheimers Dement*. 2016;12(1):75-84. PMID: 26079412.
15. Hammond FM, Alexander DN, Cutler AJ, D'Amico S, Doody RS, Sauve W, et al. Erratum to: PRISM II: an open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. *BMC Neurol*. 2016;16(1):160. PMID: 27590297.
16. Hammond FM, Alexander DN, Cutler AJ, D'Amico S, Doody RS, Sauve W, et al. PRISM II: An open-label study to assess effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with dementia, stroke or traumatic brain injury. *BMC Neurol*. 2016;16(1):89. PMID: 27276999.
17. Liang FW, Chan W, Chen PJ, Zimmerman C, Waring S, Doody R. Cognitively-related basic activities of daily living impairment greatly increases the risk of death in Alzheimer's disease. *PLoS One*. 2016;11(8):e0160671. PMID: 27571265.
18. Luo S, Chan W, Detry MA, Massman PJ, Doody RS. Binomial regression with a misclassified covariate and outcome. *Stat Methods Med Res*. 2016;25(1):101-17. PMID: 22421539.
19. Doody RS, Demirovic J, Ballantyne CM, Chan W, Barber R, Powell S, et al. Lipoprotein-associated phospholipase A2, homocysteine, and Alzheimer's disease. *Alzheimers Dement (Amst)*. 2015;1(4):464-71. PMID: 27239525.
20. Doody RS, Raman R, Sperling RA, Seimers E, Sethuraman G, Mohs R, et al. Peripheral and central effects of gamma-secretase inhibition by semagacestat in Alzheimer's disease. *Alzheimers Res Ther*. 2015;7(1):36. PMID: 26064192.
21. Grill JD, Raman R, Ernstrom K, Aisen P, Dowsett SA, Chen YF, et al. Comparing recruitment, retention, and safety reporting among geographic regions in multinational Alzheimer's disease clinical trials. *Alzheimers Res Ther*. 2015;7(1):39. PMID: 26120368.
22. Henley DB, Dowsett SA, Chen YF, Liu-Seifert H, Grill JD, Doody RS, et al. Alzheimer's disease progression by geographical region in a clinical trial setting. *Alzheimers Res Ther*. 2015;7(1):43. PMID: 26120369.
23. Liu-Seifert H, Siemers E, Holdridge KC, Andersen SW, Lipkovich I, Carlson C, et al. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years. *Alzheimers Dement (N Y)*. 2015;1(2):111-21. DOI: 10.1016/j.trci.2015.06.006.
24. Lowe DA, Balsis S, Benge JF, Doody RS. Adding delayed recall to the ADAS-cog improves measurement precision in mild Alzheimer's disease: Implications for predicting instrumental activities of daily living. *Psychol Assess*. 2015;27(4):1234-40. PMID: 25938338.
25. Salmeron S, Huedo I, Lopez-Utiel M, Soler-Moratalla I, Flores-Ruano T, Fernandez-Sanchez M, et al. Validation of the Spanish Version of the Baylor Profound Mental Status Examination. *J Alzheimers Dis*. 2015;49(1):73-8. PMID: 26444781.
26. Vellas B, Bateman R, Blennow K, Frisoni G, Johnson K, Katz R, et al. Endpoints for pre-dementia ad trials: A report from the EU/US/CTAD task force. *J Prev Alz Dis*. 2015;2(2):128-35.
27. Boxer AL, Lang AE, Grossman M, Knopman DS, Miller BL, Schneider LS, et al. Davunetide in patients with progressive supranuclear palsy: A randomised, double-blind, placebo-controlled phase 2/3 trial. *Lancet Neurol*. 2014;13(7):676-85. PMID: 24873720.
28. Doody RS, Farlow M, Aisen PS, Alzheimer's Disease Cooperative Study Data Analysis and Publication Committee. Phase 3 trials of solanezumab and bapineuzumab for Alzheimer's disease. *N Engl J Med*. 2014;370(15):1460. PMID: 24716687.
29. Doody RS, Thomas RG, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. Phase 3 trials of solanezumab for mild-to-moderate Alzheimer's disease. *N Engl J Med*. 2014;370(4):311-21. PMID: 24450890.
30. O'Bryant SE, Xiao G, Barber R, Cullum CM, Weiner M, Hall J, et al. Molecular neuropsychology: Creation of test-specific blood biomarker algorithms. *Dement Geriatr Cogn Disord*. 2014;37(1-2):45-57. PMID: 24107792.
31. Szigeti K, Kellermayer B, Lentini JM, Trummer B, Lal D, Doody RS, et al. Ordered subset analysis of copy number variation association with age at onset of Alzheimer's disease. *J Alzheimers Dis*. 2014;41(4):1063-71. PMID: 24787912.
32. Doody RS, Aisen PS, Iwatsubo T. Semagacestat for treatment of Alzheimer's disease. *N Engl J Med*. 2013;369(17):1661. PMID: 24152267.
33. Doody RS, Raman R, Farlow M, Iwatsubo T, Vellas B, Joffe S, et al. A phase 3 trial of semagacestat for treatment of Alzheimer's disease. *N Engl J Med*. 2013;369(4):341-50. PMID: 23883379.
34. Ferris S, Cummings J, Christensen D, Doody R, Farlow M, Sabbagh M, et al. Effects of donepezil 23 mg on Severe Impairment Battery domains in patients with moderate to severe Alzheimer's disease: Evaluating the

- impact of baseline severity. *Alzheimers Res Ther.* 2013;5(1):12. PMID: 23433097.
35. Pavlik V, Massman P, Barber R, Doody R. Differences in the association of peripheral insulin and cognitive function in non-diabetic Alzheimer's disease cases and normal controls. *J Alzheimers Dis.* 2013;34(2):449-56. PMID: 23241558.
 36. Rountree SD, Atri A, Lopez OL, Doody RS. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression. *Alzheimers Dement.* 2013;9(3):338-45. PMID: 23102979.
 37. Sabbagh M, Cummings J, Christensen D, Doody R, Farlow M, Liu L, et al. Evaluating the cognitive effects of donepezil 23 mg/d in moderate and severe Alzheimer's disease: analysis of effects of baseline features on treatment response. *BMC Geriatr.* 2013;13:56. PMID: 23742728.
 38. Senanarong V, Harnphadungkit K, Pongvarin N, Vannasaeng S, Chongwisal S, Chakorn T, et al. The dementia and disability project in Thai elderly: Rational, design, methodology and early results. *BMC Neurol.* 2013;13:3. PMID: 23305293.
 39. Spiegel R, Doody RS, Hendrix S, Kahle-Wroblewski K. Modeling the course of Alzheimer's disease to improve clinical trials: Symposium report. *Alzheimers Res Ther.* 2013;5(3):29. PMID: 23767782.
 40. Szigeti K, Lal D, Li Y, Doody RS, Wilhelmsen K, Yan L, et al. Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease. *J Alzheimers Dis.* 2013;33(2):517-23. PMID: 23202439.
 41. Vellas B, Carrillo MC, Sampaio C, Brashear HR, Siemers E, Hampel H, et al. Designing drug trials for Alzheimer's disease: What we have learned from the release of the phase III antibody trials: A report from the EU/US/CTAD Task Force. *Alzheimers Dement.* 2013;9(4):438-44. PMID: 23809364.
 42. Zhang X, Li L, Zhang X, Xie W, Li L, Yang D, et al. Prenatal hypoxia may aggravate the cognitive impairment and Alzheimer's disease neuropathology in APPSwe/PS1A246E transgenic mice. *Neurobiol Aging.* 2013;34(3):663-78. PMID: 22795785.
 43. Atri A, Rountree SD, Lopez OL, Doody RS. Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies. *Neurodegener Dis.* 2012;10(1-4):170-4. PMID: 22327239.
 44. Balsis S, Unger AA, Bengtson JF, Geraci L, Doody RS. Gaining precision on the Alzheimer's Disease Assessment Scale-cognitive: a comparison of item response theory-based scores and total scores. *Alzheimers Dement.* 2012;8(4):288-94. PMID: 22465173.
 45. Doody RS, Cummings JL, Farlow MR. Reviewing the role of donepezil in the treatment of Alzheimer's disease. *Curr Alzheimer Res.* 2012;9(7):773-81. PMID: 22175653.
 46. Doody RS, Geldmacher DS, Farlow MR, Sun Y, Moline M, Mackell J. Efficacy and safety of donepezil 23 mg versus donepezil 10 mg for moderate-to-severe Alzheimer's disease: A subgroup analysis in patients already taking or not taking concomitant memantine. *Dement Geriatr Cogn Disord.* 2012;33(2-3):164-73. PMID: 22572767.
 47. Havins WN, Massman PJ, Doody R. Factor structure of the Geriatric Depression Scale and relationships with cognition and function in Alzheimer's disease. *Dement Geriatr Cogn Disord.* 2012;34(5-6):360-72. PMID: 23235472.
 48. Hurko O, Black SE, Doody R, Doraiswamy PM, Gamst A, Kaye J, et al. The ADNI Publication Policy: Commensurate recognition of critical contributors who are not authors. *Neuroimage.* 2012;59(4):4196-200. PMID: 22100665.
 49. Li Y, Shaw CA, Sheffer I, Sule N, Powell SZ, Dawson B, et al. Integrated copy number and gene expression analysis detects a CREB1 association with Alzheimer's disease. *Transl Psychiatry.* 2012;2:e192. PMID: 23168992.
 50. Lowe DA, Balsis S, Miller TM, Bengtson JF, Doody RS. Greater precision when measuring dementia severity: Establishing item parameters for the Clinical Dementia Rating Scale. *Dement Geriatr Cogn Disord.* 2012;34(2):128-34. PMID: 23006935.
 51. Rountree SD, Chan W, Pavlik VN, Darby EJ, Doody RS. Factors that influence survival in a probable Alzheimer disease cohort. *Alzheimers Res Ther.* 2012;4(3):16. PMID: 22594761.
 52. Aisen PS, Andrieu S, Sampaio C, Carrillo M, Khachaturian ZS, Dubois B, et al. Report of the task force on designing clinical trials in early (predementia) AD. *Neurology.* 2011;76(3):280-6. PMID: 21178097.
 53. Balsis S, Miller TM, Bengtson JF, Doody RS. Dementia staging across three different methods. *Dement Geriatr Cogn Disord.* 2011;31(5):328-33. PMID: 21555887.
 54. Doody RS, Cole PE, Miller DS, Siemers E, Black R, Feldman H, et al. Global issues in drug development for Alzheimer's disease. *Alzheimers Dement.* 2011;7(2):197-207. PMID: 21414556.
 55. Doody RS, Ferris SH, Salloway S, Meuser TM, Murthy AK, Li C, et al. Identifying amnesic mild cognitive impairment in primary care: A feasibility study. *Clin Drug Investig.* 2011;31(7):483-91. PMID: 21627337.
 56. Mielke MM, Haughey NJ, Bandaru VV, Weinberg DD, Darby E, Zaidi N, et al. Plasma sphingomyelins are associated with cognitive progression in Alzheimer's disease. *J Alzheimers Dis.* 2011;27(2):259-69. PMID: 21841258.
 57. Miller TM, Balsis S, Lowe DA, Bengtson JF, Doody RS. Item response theory reveals variability of functional impairment within clinical dementia rating scale stages. *Dement Geriatr Cogn Disord.* 2011;32(5):362-6.

PMID: 22311305.

58. O'Bryant SE, Xiao G, Barber R, Huebinger R, Wilhelmsen K, Edwards M, et al. A blood-based screening tool for Alzheimer's disease that spans serum and plasma: Findings from TARC and ADNI. *PLoS One*. 2011;6(12):e28092. PMID: 22163278.
59. O'Bryant SE, Xiao G, Barber R, Reisch J, Hall J, Cullum CM, et al. A blood-based algorithm for the detection of Alzheimer's disease. *Dement Geriatr Cogn Disord*. 2011;32(1):55-62. PMID: 21865746.
60. Pavlik VN, Doody RS. Progress in understanding variability in cognitive responses to cholinesterase inhibitor treatment. *Alzheimers Res Ther*. 2011;3(5):30. PMID: 21999183.
61. Shaw CA, Li Y, Wiszniewska J, Chasse S, Zaidi SN, Jin W, et al. Olfactory copy number association with age at onset of Alzheimer disease. *Neurology*. 2011;76(15):1302-9. PMID: 21482944.
62. Szigeti K, Doody RS. Should EOAD patients be included in clinical trials? *Alzheimers Res Ther*. 2011;3(1):4. PMID: 21345175.
63. Szigeti K, Doody RS. Should persons with autosomal dominant AD be included in clinical trials? Authors' response. *Alzheimers Res Ther*. 2011;3(3):19. PMID: 21631907.
64. Zhang X, Heng X, Li T, Li L, Yang D, Zhang X, et al. Long-term treatment with lithium alleviates memory deficits and reduces amyloid-beta production in an aged Alzheimer's disease transgenic mouse model. *J Alzheimers Dis*. 2011;24(4):739-49. PMID: 21321394.
65. Doody RS, Ferris S, Salloway S, Yijun S, Goldman R, Yikang X, et al. Safety and tolerability of donepezil in mild cognitive impairment: Open-label extension study. *Am J Alzheimers Dis Other Demen*. 2010;25(2):155-9. PMID: 19949165.
66. Doody RS, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Correction: Predicting progression of Alzheimer's disease. *Alzheimers Res Ther*. 2010;2(3):14. PMID: 20470369.
67. Doody RS, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Predicting progression of Alzheimer's disease. *Alzheimers Res Ther*. 2010;2(1):2. PMID: 20178566.
68. Doody RS. Clinical trials in AD. *Rinsho Shinkeigaku*. 2010;50(11):835. PMID: 21921461.
69. Doody RS. Evolving early (pre-dementia) Alzheimer's disease trials: Suit the outcomes to the population and study design. *J Nutr Health Aging*. 2010;14(4):299-302. PMID: 20306000.
70. Feldman HH, Doody RS, Kivipelto M, Sparks DL, Waters DD, Jones RW, et al. Randomized controlled trial of atorvastatin in mild to moderate Alzheimer disease: LEADe. *Neurology*. 2010;74(12):956-64. PMID: 20200346.
71. Kunik ME, Snow AL, Davila JA, McNeese T, Steele AB, Balasubramanyam V, et al. Consequences of aggressive behavior in patients with dementia. *J Neuropsychiatry Clin Neurosci*. 2010;22(1):40-7. PMID: 20160208.
72. Kunik ME, Snow AL, Davila JA, Steele AB, Balasubramanyam V, Doody RS, et al. Causes of aggressive behavior in patients with dementia. *J Clin Psychiatry*. 2010;71(9):1145-52. PMID: 20361896.
73. Kwon OD, Khaleeq A, Chan W, Pavlik VN, Doody RS. Apolipoprotein E polymorphism and age at onset of Alzheimer's disease in a quadriethnic sample. *Dement Geriatr Cogn Disord*. 2010;30(6):486-91. PMID: 21252542.
74. O'Bryant SE, Xiao G, Barber R, Reisch J, Doody R, Fairchild T, et al. A serum protein-based algorithm for the detection of Alzheimer disease. *Arch Neurol*. 2010;67(9):1077-81. PMID: 20837851.
75. Wolk DA, Dickerson BC, Alzheimer's Disease Neuroimaging Initiative. Apolipoprotein E (APOE) genotype has dissociable effects on memory and attentional-executive network function in Alzheimer's disease. *Proc Natl Acad Sci U S A*. 2010;107(22):10256-61. PMID: 20479234.
76. Bengtson JF, Balsis S, Geraci L, Massman PJ, Doody RS. How well do the ADAS-cog and its subscales measure cognitive dysfunction in Alzheimer's disease? *Dement Geriatr Cogn Disord*. 2009;28(1):63-9. PMID: 19641319.
77. Doody RS, Ferris SH, Salloway S, Sun Y, Goldman R, Watkins WE, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. *Neurology*. 2009;72(18):1555-61. PMID: 19176895.
78. Doody RS. Commentary on "a roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Centers of excellence in Alzheimer's disease: It is time to better integrate patient care and clinical research to improve the prevention and treatment of Alzheimer's disease. *Alzheimers Dement*. 2009;5(2):133-6. PMID: 19328443.
79. Doody RS. Dimebon as a potential therapy for Alzheimer's disease. *CNS Spectr*. 2009;14(8 Suppl 7):14-6; discussion 16-8. PMID: 19890242.
80. Khachaturian ZS, Snyder PJ, Doody R, Aisen P, Comer M, Dwyer J, et al. A roadmap for the prevention of dementia II: Leon Thal Symposium 2008. *Alzheimers Dement*. 2009;5(2):85-92. PMID: 19328434.
81. Na HR, Lee SH, Lee JS, Doody RS, Kim SY. Korean version of the Baylor Profound Mental Status Examination: A brief staging measure for patients with severe Alzheimer's disease. *Dement Geriatr Cogn Disord*. 2009;27(1):69-75. PMID: 19145080.
82. Pavlik VN, Doody RS, Rountree SD, Darby EJ. Vitamin E use is associated with improved survival in an Alzheimer's disease cohort. *Dement Geriatr Cogn Disord*. 2009;28(6):536-40. PMID: 20016184.

83. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. *Alzheimers Res Ther*. 2009;1(2):7. PMID: 19845950.
84. Salloway S, Sperling R, Gilman S, Fox NC, Blennow K, Raskind M, et al. A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease. *Neurology*. 2009;73(24):2061-70. PMID: 19923550.
85. Schneider LS, Raman R, Schmitt FA, Doody RS, Insel P, Clark CM, et al. Characteristics and performance of a modified version of the ADCS-CGIC CIBIC+ for mild cognitive impairment clinical trials. *Alzheimer Dis Assoc Disord*. 2009;23(3):260-7. PMID: 19812469.
86. Snyder PJ, Papp KV, Bartkowiak J, Jackson CE, Doody RS. Commentary on "A roadmap for the prevention of dementia II. Leon Thal Symposium 2008." Recruitment of participants for Alzheimer's disease clinical trials: The role of trust in caregivers, clinical researchers, regulatory authorities, and industry sponsors. *Alzheimers Dement*. 2009;5(2):122-4. PMID: 19328439.
87. Doody RS, Corey-Bloom J, Zhang R, Li H, Ieni J, Schindler R. Safety and tolerability of donepezil at doses up to 20 mg/day: Results from a pilot study in patients with Alzheimer's disease. *Drugs Aging*. 2008;25(2):163-74. PMID: 18257603.
88. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, et al. Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: A randomized, double-blind, placebo-controlled study. *Lancet*. 2008;372(9634):207-15. PMID: 18640457.
89. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM. Meta-analysis of six-month memantine trials in Alzheimer's disease. *Alzheimers Dement*. 2008;3(1):7-17.
90. Doody RS. Cholinesterase inhibitors and memantine: Best practices. *CNS Spectr*. 2008;13(10 Suppl 16):34-5. PMID: 18955960.
91. Doody RS. We should not distinguish between symptomatic and disease-modifying treatments in Alzheimer's disease drug development. *Alzheimers Dement*. 2008;4(1 Suppl 1):S21-5. PMID: 18631995.
92. Jack CR, Jr, Petersen RC, Grundman M, Jin S, Gamst A, et al. Longitudinal MRI findings from the vitamin E and donepezil treatment study for MCI. *Neurobiol Aging*. 2008;29(9):1285-95. PMID: 17452062.
93. Jones RW, Kivipelto M, Feldman H, Sparks L, Doody R, Waters DD, et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Design and baseline characteristics. *Alzheimers Dement*. 2008;4(2):145-53. PMID: 18631958.
94. Kelly PA, Dyer CB, Pavlik V, Doody R, Jogerst G. Exploring self-neglect in older adults: Preliminary findings of the self-neglect severity scale and next steps. *J Am Geriatr Soc*. 2008;56 Suppl 2:S253-60. PMID: 19016968.
95. Khachaturian ZS, Petersen RC, Gauthier S, Buckholtz N, Corey-Bloom JP, Evans B, et al. A roadmap for the prevention of dementia: The inaugural Leon Thal Symposium. *Alzheimers Dement*. 2008;4(3):156-63. PMID: 18631960.
96. O'Bryant SE, Waring SC, Cullum CM, Hall J, Lacritz L, Massman PJ, et al. Staging dementia using Clinical Dementia Rating Scale Sum of Boxes scores: a Texas Alzheimer's research consortium study. *Arch Neurol*. 2008;65(8):1091-5. PMID: 18695059.
97. Yan JH, Rountree S, Massman P, Doody RS, Li H. Alzheimer's disease and mild cognitive impairment deteriorate fine movement control. *J Psychiatr Res*. 2008;42(14):1203-12. PMID: 18280503.
98. Atchison TB, Massman PJ, Doody RS. Baseline cognitive function predicts rate of decline in basic-care abilities of individuals with dementia of the Alzheimer's type. *Arch Clin Neuropsychol*. 2007;22(1):99-107. PMID: 17174522.
99. Black SE, Doody R, Li H, McRae T, Jambor KM, Xu Y, et al. Donepezil preserves cognition and global function in patients with severe Alzheimer disease. *Neurology*. 2007;69(5):459-69. PMID: 17664405.
100. Cummings JL, Doody R, Clark C. Disease-modifying therapies for Alzheimer disease: challenges to early intervention. *Neurology*. 2007;69(16):1622-34. PMID: 17938373.
101. Park KW, Pavlik VN, Rountree SD, Darby EJ, Doody RS. Is functional decline necessary for a diagnosis of Alzheimer's disease? *Dement Geriatr Cogn Disord*. 2007;24(5):375-9. PMID: 17914262.
102. Rountree SD, Waring SC, Chan WC, Lupo PJ, Darby EJ, Doody RS. Importance of subtle amnesic and nonamnesic deficits in mild cognitive impairment: Prognosis and conversion to dementia. *Dement Geriatr Cogn Disord*. 2007;24(6):476-82. PMID: 17992015.
103. Dyer CB, Kelly PA, Pavlik VN, Lee J, Doody RS, Regev T, et al. The making of a self-neglect severity scale. *J Elder Abuse Negl*. 2006;18(4):13-23. PMID: 17972656.
104. Fillit HM, Doody RS, Binaso K, Crooks GM, Ferris SH, Farlow MR, et al. Recommendations for best practices in the treatment of Alzheimer's disease in managed care. *Am J Geriatr Pharmacother*. 2006;4 Suppl A:S9-S24; quiz S25-S28. PMID: 17157793.
105. Geldmacher DS, Frolich L, Doody RS, Erkinjuntti T, Vellas B, Jones RW, et al. Realistic expectations for treatment success in Alzheimer's disease. *J Nutr Health Aging*. 2006;10(5):417-29. PMID: 17066215.
106. Pavlik VN, Doody RS, Massman PJ, Chan W. Influence of premorbid IQ and education on progression of

- Alzheimer's disease. *Dement Geriatr Cogn Disord*. 2006;22(4):367-77. PMID: 16954693.
107. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ. A 24-week open-label extension study of memantine in moderate to severe Alzheimer disease. *Arch Neurol*. 2006;63(1):49-54. PMID: 16401736.
 108. Schneider LS, Clark CM, Doody R, Ferris SH, Morris JC, Raman R, et al. ADCS Prevention Instrument Project: ADCS-clinicians' global impression of change scales (ADCS-CGIC), self-rated and study partner-rated versions. *Alzheimer Dis Assoc Disord*. 2006;20(4 Suppl 3):S124-38. PMID: 17135806.
 109. Doody R, Pavlik V, Massman P, Kenan M, Yeh S, Powell S, et al. Changing patient characteristics and survival experience in an Alzheimer's center patient cohort. *Dement Geriatr Cogn Disord*. 2005;20(2-3):198-208. PMID: 16088145.
 110. Doody RS. Refining treatment guidelines in Alzheimer's disease. *Geriatrics*. 2005;Suppl:14-20. PMID: 16025771.
 111. Graham DP, Kunik ME, Doody R, Snow AL. Self-reported awareness of performance in dementia. *Brain Res Cogn Brain Res*. 2005;25(1):144-52. PMID: 15919186.
 112. Hoyt BD, Massman PJ, Schatschneider C, Cooke N, Doody RS. Individual growth curve analysis of APOE epsilon 4-associated cognitive decline in Alzheimer disease. *Arch Neurol*. 2005;62(3):454-9. PMID: 15767511.
 113. Pavlik VN, Hyman DJ, Doody R. Cardiovascular risk factors and cognitive function in adults 30-59 years of age (NHANES III). *Neuroepidemiology*. 2005;24(1-2):42-50. PMID: 15459509.
 114. Petersen RC, Thomas RG, Grundman M, Bennett D, Doody R, Ferris S, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. *N Engl J Med*. 2005;352(23):2379-88. PMID: 15829527.
 115. Roman GC, Wilkinson DG, Doody RS, Black SE, Salloway SP, Schindler RJ. Donepezil in vascular dementia: Combined analysis of two large-scale clinical trials. *Dement Geriatr Cogn Disord*. 2005;20(6):338-44. PMID: 16192723.
 116. Snow AL, Graham DP, Molinari VA, Orengo CA, Doody RS, Norris MP, et al. Factors affecting deficit awareness in persons with dementia. *Dement Geriatr Cogn Disord*. 2005;20(2-3):133-9. PMID: 16020941.
 117. Snow AL, Kunik ME, Molinari VA, Orengo CA, Doody R, Graham DP, et al. Accuracy of self-reported depression in persons with dementia. *J Am Geriatr Soc*. 2005;53(3):389-96. PMID: 15743279.
 118. Waring SC, Doody RS, Pavlik VN, Massman PJ, Chan W. Survival among patients with dementia from a large multi-ethnic population. *Alzheimer Dis Assoc Disord*. 2005;19(4):178-83. PMID: 16327343.
 119. Doody R, Wirth Y, Schmitt F, Mobius HJ. Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. *Dement Geriatr Cogn Disord*. 2004;18(2):227-32. PMID: 15256834.
 120. Doody RS, Dunn JK, Huang E, Azher S, Kataki M. A method for estimating duration of illness in Alzheimer's disease. *Dement Geriatr Cogn Disord*. 2004;17(1-2):1-4. PMID: 14560058.
 121. Graham DP, Cully JA, Snow AL, Massman P, Doody R. The Alzheimer's Disease Assessment Scale-Cognitive subscale: Normative data for older adult controls. *Alzheimer Dis Assoc Disord*. 2004;18(4):236-40. PMID: 15592137.
 122. Grundman M, Petersen RC, Ferris SH, Thomas RG, Aisen PS, Bennett DA, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. *Arch Neurol*. 2004;61(1):59-66. PMID: 14732621.
 123. Snow AL, Norris MP, Doody R, Molinari VA, Orengo CA, Kunik ME. Dementia Deficits Scale. Rating self-awareness of deficits. *Alzheimer Dis Assoc Disord*. 2004;18(1):22-31. PMID: 15198084.
 124. Clark CM, Xie S, Chittams J, Ewbank D, Peskind E, Galasko D, et al. Cerebrospinal fluid tau and beta-amyloid: How well do these biomarkers reflect autopsy-confirmed dementia diagnoses? *Arch Neurol*. 2003;60(12):1696-702. PMID: 14676043.
 125. Davis RN, Massman PJ, Doody RS. Effects of blood pressure on neuropsychological functioning in Alzheimer's disease. *Arch Clin Neuropsychol*. 2003;18(1):19-32. PMID: 14591475.
 126. Davis RN, Massman PJ, Doody RS. WAIS-R factor structure in Alzheimer's disease patients: A comparison of alternative models and an assessment of their generalizability. *Psychol Aging*. 2003;18(4):836-43. PMID: 14692868.
 127. Doody RS. Current treatments for Alzheimer's disease: Cholinesterase inhibitors. *J Clin Psychiatry*. 2003;64 Suppl 9:11-7. PMID: 12934969.
 128. Doody RS. Update on Alzheimer drugs (donepezil). *Neurologist*. 2003;9(5):225-9. PMID: 12971832.
 129. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Mobius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. *N Engl J Med*. 2003;348(14):1333-41. PMID: 12672860.
 130. Smith RG, Roher AE, Appel SH, Doody RS, Killian JM, Corey-Bloom J, et al. Autonomic sudomotor dysfunction in Alzheimer's disease. *Curr Med Chem - Immun Endoc Metab Agents*. 2003;3(1):77-84.
 131. Wilkinson D, Doody R, Helme R, Taubman K, Mintzer J, Kertesz A, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. *Neurology*. 2003;61(4):479-86. PMID: 12939421.
 132. Quinn J, Moore M, Benson DF, Clark CM, Doody R, Jagust W, et al. A videotaped CIBIC for dementia patients: Validity and reliability in a simulated clinical trial. *Neurology*. 2002;58(3):433-7. PMID: 11839844.

133. Weiner MF, Doody RS, Sairam R, Foster B, Liao TY. Prevalence and incidence of major depressive disorder in Alzheimer's disease: findings from two databases. *Dement Geriatr Cogn Disord*. 2002;13(1):8-12. PMID: 11731709.
134. Davis RN, Massman PJ, Doody RS. Cognitive intervention in Alzheimer disease: a randomized placebo-controlled study. *Alzheimer Dis Assoc Disord*. 2001;15(1):1-9. PMID: 11236819.
135. Doody RS, Dunn JK, Clark CM, Farlow M, Foster NL, Liao T, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease. *Dement Geriatr Cogn Disord*. 2001;12(4):295-300. PMID: 11351141.
136. Doody RS, Geldmacher DS, Gordon B, Perdomo CA, Pratt RD. Open-label, multicenter, phase 3 extension study of the safety and efficacy of donepezil in patients with Alzheimer disease. *Arch Neurol*. 2001;58(3):427-33. PMID: 11255446.
137. Doody RS, Massman P, Dunn JK. A method for estimating progression rates in Alzheimer disease. *Arch Neurol*. 2001;58(3):449-54. PMID: 11255449.
138. Doody RS, Stevens JC, Beck C, Dubinsky RM, Kaye JA, Gwyther L, et al. Practice parameter: Management of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology*. 2001;56(9):1154-66. PMID: 11342679.
139. Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, et al. A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients. *Neurology*. 2001;57(3):481-8. PMID: 11502917.
140. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, et al. Current concepts in mild cognitive impairment. *Arch Neurol*. 2001;58(12):1985-92. PMID: 11735772.
141. Tangalos E, Doody R, Tariot P. Alzheimer's disease in long-term care: Maximizing treatment options. *J Am Med Dir Assoc*. 2001;2(4):H17-20. PMID: 12812557.
142. Doody RS, Azher SN, Haykal HA, Dunn JK, Liao T, Schneider L. Does APO epsilon4 correlate with MRI changes in Alzheimer's disease? *J Neurol Neurosurg Psychiatry*. 2000;69(5):668-71. PMID: 11032626.
143. Doody RS. Mortality from pneumonia and hip fractures in patients with advanced dementia. *Jama*. 2000;284(19):2447; author reply 2448. PMID: 11074768.
144. Doody RS. The issue of representation in brain research. *Brain Cogn*. 2000;42(1):26-8. PMID: 10739589.
145. Hanna PA, Doody RS. Alien limb sign. *Adv Neurol*. 2000;82:135-45. PMID: 10624477.
146. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. *Alzheimer's Disease Cooperative Study*. *Jama*. 2000;283(8):1007-15. PMID: 10697060.
147. Rogers SL, Doody RS, Pratt RD, Ieni JR. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. *Eur Neuropsychopharmacol*. 2000;10(3):195-203. PMID: 10793322.
148. Doody RS, Strehlow SL, Massman PJ, Feher EP, Clark C, Roy JR. Baylor profound mental status examination: A brief staging measure for profoundly demented Alzheimer disease patients. *Alzheimer Dis Assoc Disord*. 1999;13(1):53-9. PMID: 10192643.
149. Doody RS, Vacca JL, Massman PJ, Liao TY. The influence of handedness on the clinical presentation and neuropsychology of Alzheimer disease. *Arch Neurol*. 1999;56(9):1133-7. PMID: 10488815.
150. Doody RS. Clinical benefits of a new piperidine-class AChE inhibitor. *Eur Neuropsychopharmacol*. 1999;9 Suppl 2:S69-77. PMID: 10332937.
151. Doody RS. Clinical profile of donepezil in the treatment of Alzheimer's disease. *Gerontology*. 1999;45 Suppl 1:23-32. PMID: 9876215.
152. Doody RS. Therapeutic standards in Alzheimer disease. *Alzheimer Dis Assoc Disord*. 1999;13 Suppl 2:S20-6. PMID: 10622675.
153. Doody R, Whitehouse PJ, Chen Q, Wang L, Wu Q, Rosser M, et al. Alzheimer disease-related activities in China: a report from the International Working Group on the Harmonization of Dementia Drug Guidelines. *Alzheimer Dis Assoc Disord*. 1998;12(4):263-5. PMID: 9876954.
154. Doody RS, Massman PJ, Mawad M, Nance M. Cognitive consequences of subcortical magnetic resonance imaging changes in Alzheimer's disease: comparison to small vessel ischemic vascular dementia. *Neuropsychiatry Neuropsychol Behav Neurol*. 1998;11(4):191-9. PMID: 9845410.
155. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil improves cognition and global function in Alzheimer disease: a 15-week, double-blind, placebo-controlled study. *Donepezil Study Group*. *Arch Intern Med*. 1998;158(9):1021-31. PMID: 9588436.
156. Rogers SL, Farlow MR, Doody RS, Mohs R, Friedhoff LT. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. *Donepezil Study Group*. *Neurology*. 1998;50(1):136-45. PMID: 9443470.
157. Amaducci L, Baldereschi M, Doody R, Chandra V, Gaines AD. Cultural issues in the clinical diagnosis of Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. *Alzheimer Dis Assoc Disord*. 1997;11 Suppl 3:19-21. PMID: 9305509.
158. Antuono P, Doody R, Gilman S, Huff J, Scheltens P, Ueda K, et al. Diagnostic criteria for dementia in clinical

- trials. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. *Alzheimer Dis Assoc Disord*. 1997;11 Suppl 3:22-5. PMID: 9305510.
159. Clark CM, Ewbank D, Lerner A, Doody R, Henderson VW, Panisset M, et al. The relationship between extrapyramidal signs and cognitive performance in patients with Alzheimer's disease enrolled in the CERAD Study. Consortium to Establish a Registry for Alzheimer's Disease. *Neurology*. 1997;49(1):70-5. PMID: 9222172.
160. Doody RS. Treatment of Alzheimer's disease. *Neurologist*. 1997;3(6):333-43.
161. Perkins P, Annegers JF, Doody RS, Cooke N, Aday L, Vernon SW. Incidence and prevalence of dementia in a multiethnic cohort of municipal retirees. *Neurology*. 1997;49(1):44-50. PMID: 9222168.
162. Reisberg B, Schneider L, Doody R, Anand R, Feldman H, Haraguchi H, et al. Clinical global measures of dementia. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. *Alzheimer Dis Assoc Disord*. 1997;11 Suppl 3:8-18. PMID: 9305508.
163. Sabbagh MN, Lynn P, Jhingran S, Massman P, Villanueva-Meyer J, Olup J, et al. Correlations between SPECT regional cerebral blood flow and psychometric testing in patients with Alzheimer's disease. *J Neuropsychiatry Clin Neurosci*. 1997;9(1):68-74. PMID: 9017531.
164. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. *Alzheimer Dis Assoc Disord*. 1997;11 Suppl 2:S22-32. PMID: 9236949.
165. Strite D, Massman PJ, Cooke N, Doody RS. Neuropsychological asymmetry in Alzheimer's disease: Verbal versus visuoconstructional deficits across stages of dementia. *J Int Neuropsychol Soc*. 1997;3(5):420-7. PMID: 9322400.
166. Thal LJ, Carta A, Doody R, Leber P, Mohs R, Schneider L, et al. Prevention protocols for Alzheimer disease. Position paper from the International Working Group on Harmonization of Dementia Drug Guidelines. *Alzheimer Dis Assoc Disord*. 1997;11 Suppl 3:46-9. PMID: 9305516.
167. Katakami M, Winikates J, Kirkpatrick J, Doody RS. Longitudinal study of aphasia in Creutzfeldt-Jakob disease. *Neuropsychiatry Neuropsychol Behav Neurol*. 1996;9(4):284-7.
168. Massman PJ, Doody RS. Hemispheric asymmetry in Alzheimer's disease is apparent in motor functioning. *J Clin Exp Neuropsychol*. 1996;18(1):110-21. PMID: 8926290.
169. Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological functioning in cortical-basal ganglionic degeneration: Differentiation from Alzheimer's disease. *Neurology*. 1996;46(3):720-6. PMID: 8618672.
170. Olin JT, Schneider LS, Doody RS, Clark CM, Ferris SH, Morris JC, et al. Clinical evaluation of global change in Alzheimer's disease: identifying consensus. *J Geriatr Psychiatry Neurol*. 1996;9(4):176-80. PMID: 8970010.
171. Doody RS, Massman P, Mahurin R, Law S. Positive and negative neuropsychiatric features in Alzheimer's disease. *J Neuropsychiatry Clin Neurosci*. 1995;7(1):54-60. PMID: 7711492.
172. Kotrla KJ, Chacko RC, Harper RG, Doody R. Clinical variables associated with psychosis in Alzheimer's disease. *Am J Psychiatry*. 1995;152(9):1377-9. PMID: 7653698.
173. Kotrla KJ, Chacko RC, Harper RG, Jhingran S, Doody R. SPECT findings on psychosis in Alzheimer's disease. *Am J Psychiatry*. 1995;152(10):1470-5. PMID: 7573586.
174. Shaibani A, Sabbagh M, Doody RS. Laughter and crying in neurologic disorders. *Neuropsychiatry Neuropsychol Behav Neurol*. 1994;7(4):243-50.
175. Doody RS. A reappraisal of localization theory with reference to aphasia. Part 1: Historical considerations. *Brain Lang*. 1993;44(3):296-326. PMID: 8513406.
176. Doody RS. A reappraisal of localization theory with reference to aphasia. Part 2: Language theories from outside neurology. *Brain Lang*. 1993;44(3):327-48. PMID: 8513407.
177. Davis KL, Thal LJ, Gamzu ER, Davis CS, Woolson RF, Gracon SI, et al. A double-blind, placebo-controlled multicenter study of tacrine for Alzheimer's disease. The Tacrine Collaborative Study Group. *N Engl J Med*. 1992;327(18):1253-9. PMID: 1406817.
178. Doody RS, Hrachovy RA, Feher EP. Recurrent fluent aphasia associated with a seizure focus. *Brain Lang*. 1992;42(4):419-30. PMID: 1611466.
179. Doody RS, Jankovic J. The alien hand and related signs. *J Neurol Neurosurg Psychiatry*. 1992;55(9):806-10. PMID: 1402972.
180. Doody RS. Sense and non-sense: Dissemination and empiricism in practice. *Ethos*. 1992;20(2):220-9.
181. Feher EP, Mahurin RK, Doody RS, Cooke N, Sims J, Pirozzolo FJ. Establishing the limits of the Mini-Mental State. Examination of 'subtests'. *Arch Neurol*. 1992;49(1):87-92. PMID: 1728269.
182. Doody RS. Aphasia as postmodern (anthropological) discourse. *J Anthropol Res*. 1991;47(3):285-303.
183. Feher EP, Doody RS, Whitehead J, Pirozzolo FJ. Progressive nonfluent aphasia with dementia: A case report. *J Geriatr Psychiatry Neurol*. 1991;4(4):236-40. PMID: 1789913.
184. Doody RS, Rosenfield DB. Spasmodic dysphonia associated with palatal myoclonus. *Ear Nose Throat J*. 1990;69(12):829-32. PMID: 2079007.
185. Feher EP, Doody R, Pirozzolo FJ, Appel SH. Mental status assessment of insight and judgment. *Clin Geriatr Med*. 1989;5(3):477-98. PMID: 2680029.

186. Ornish D, Scherwitz LW, Doody RS, Kesten D, McLanahan SM, Brown SE, et al. Effects of stress management training and dietary changes in treating ischemic heart disease. *Jama*. 1983;249(1):54-9. PMID: 6336794.
187. Doody RS, Grose NP. The family medical history: Assessing patient understanding of diabetes mellitus. *Diabetes Care*. 1981;4(2):285-8. PMID: 7215084.

BOOKS and VOLUMES

1. Doody RS, editor. *Alzheimer's dementia*. Delray Beach (FLA): Carma Publishing; 2008.

BOOK CHAPTERS and OTHER PUBLICATIONS

1. Doody RS. Alzheimer's disease and mild cognitive impairment. In: Kass JS, Mizrahi EM, editors. *Neurology secrets*. 6th ed. Philadelphia: Elsevier; 2016. p. 191-200.
2. Doody R. Dementia. In: Rolak LA, editor. *Neurology secrets*. 5th ed. Philadelphia: Mosby; 2010. p. 235-246.
3. Doody RS. Prevention and future treatment of Alzheimer's disease. In: Doody RS, editor. *Alzheimer's dementia*. Delray Beach (FLA): Carma Publishing; 2008. p. 115-140.
4. Doody RS. Alzheimer's disease. In: Johnson RT, Griffin JW, McArthur JC, editors. *Current therapy in neurologic disease*. 7th ed. Philadelphia: Mosby, Inc.; 2006. p. 311-314.
5. Doody RS, Winblad B, Jelic V. Alzheimer's and related disorders annual 2003. In: Gauthier S, Scheltens P, Cummings J, editors. *Neurodegenerative dementias*. London: Martin Dunitz (Taylor & Francis); 2004. p. 137-144.
6. Doody RS. Pathogenesis and treatment strategies for selected therapies in Alzheimer's disease. In: Iqbal K, Winblad B, editors. *Alzheimer's disease and related disorders: research advances*. Vol. 57. Bucharest, Romania: Ana Aslan International Academy of Aging; 2003. p. 633-638.
7. Grundman M, Kim H, Salmon D, Storandt M, Smith G, Ferris S, et al. The Alzheimer's disease center's neuropsychological database initiative: A resource for Alzheimer's disease prevention trials. In: Iqbal K, Sisodiya S, Winblad B, editors. *Alzheimer's disease: advances in etiology, pathogenesis, therapeutics*. New York: John Wiley & Sons; 2001. p. 129-140.
8. Doody RS. Treatment strategies in Alzheimer's disease. In: Trojanowski J, Clark C, editors. *Neurodegenerative dementias*. New York: McGraw-Hill; 2000. p. 115-126.
9. Hanna P, Doody RS. Alien limb syndrome. In: Litvan I, Goetz C, Lang A, editors. *Corticobasal degeneration*. 51st ed. Philadelphia: Lippincott-Raven, Inc.; 2000. p. 135-145.
10. Doody RS. Alzheimer's disease. In: Rakel R, editor. *Conn's current therapy*. 51st ed. Philadelphia: WB Saunders; 1999. p. 878-882.
11. Doody RS. Current therapeutic standards in the treatment of Alzheimer's disease. In: Vellas B, Fitten L, editors. *Research and practice in AD*. 51st ed. Paris: Serdi Publishing; 1999. p. 270-275.
12. Doody RS, Davidson M, Shoulson I, Whitehouse P. Harmonization of drug approval guidelines in Alzheimer's and Parkinson's diseases. In: Fisher A, Yorshida M, Hanin I, editors. *Progress in Alzheimer's and Parkinson's diseases*. New York: Plenum Press; 1998. p. 861-865.
13. Doody RS. Dementia. In: Rolak LA, editor. *Neurology secrets*. 2nd ed. Philadelphia: Hanley & Belfus; 1998. p. 199-208.
14. Doody RS. Test scores in clinical trials versus performance in real life: Can clinical global assessments bridge the gap? In: Winblad B, Wimo A, Jonsson B, Karlsson G, editors. *Health economics of dementia*. Sussex: John Wiley & Sons, Ltd.; 1998. p. 311-325.
15. Doody RS. Cholinergic therapies in the treatment of Alzheimer's disease. *Proceedings of the Fourth WHO-CC Symposium*; Sendai, Japan. Sendai, Japan: WHO-CC Monograph; 1997. p. 75-82.
16. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's disease study-clinical global impression of change (ADCS-CGIC). In: Giacobini E, Becker RE, Phillippe R, editors. *Alzheimer's disease: From molecular biology to therapy*. Boston: Birkhauser; 1996. p. 425-429.
17. Doody RS, Massman PJ. Other extrapyramidal dementias. In: Morris JC, editor. *Handbook of dementing illness*. New York: Marcel Dekker, Inc.; 1994. p. 319-334.
18. Doody RS. Alien hand. In: Molgaard CA, editor. *Neuroepidemiology: theory and method*. San Diego: Academic Press; 1993. p. 181-193.

POSTER and PLATFORM PRESENTATIONS

1. Sood A, Pavlik VN, Darby E, Chan W, Doody R. Different profiles of cognitive deficits predict progression rate in probable AD. Presented at the 2020 Alzheimer's Association International Conference (AAIC), Virtual Meeting (July 27-31, 2020).

2. Klein G, Delmar P, Rehal S, Adjelkovic M, Abi-Saab D, Bullain SS, et al. Consistently large amyloid reductions in patients with and without ARIA-E in the gantenerumab SCarlet RoAD and Marguerite RoAD open-label extension studies. *Neurology*. 2019;92(15 Suppl):S9.007. [Platform Presentation]
3. Sink S, Ostrowitzki S, Millar L, Warren F, Lin HC, Smith J, et al. Baseline characteristics from a phase III trial of crenezumab in early (prodromal-to-mild) Alzheimer's disease (CREAD). *Neurology*. 2019;92(15 Suppl):P4.1-002.
4. Abi-Saab D, Andjelkovic M, Pross N, Delmar P, Voyle N, Klein G, et al. Update on the safety and tolerability of gantenerumab in the ongoing open-label extension (OLE) of the Marguerite Road Study in patients with mild Alzheimer's disease (AD) after approximately two years of study duration. *Alzheimers Dement*. 2018;14(7 Suppl):P241.
5. Andjelkovic M, Abi-Saab D, Delmar P, Pross N, Voyle N, Klein G, et al. Update on the safety and tolerability of gantenerumab in the ongoing open-label extension of the Scarlet Road Study in patients with prodromal Alzheimer's disease after approximately two years of study duration. *Alzheimers Dement*. 2018;14(7 Suppl):P241-P242.
6. Burham, SC, Colom PM, Datigues JF, Doody R, Hansson O, et al. Concord-AD: An international network of cohorts for better understanding of Alzheimer's disease. *Alzheimers Dement*. 2018;14(7 Suppl):P1465.
7. Klein G, Delmar P, Hofmann C, Abi-Saab D, Andjelkovic M, Ristic S, et al. Twenty-four month amyloid PET results of the gantenerumab high dose open label extension studies. *Alzheimers Dement*. 2018;14(7 Suppl):P240-P241.
8. Lin H, Ostrowitzki S, Sink KM, Millar L, Warren F, Smith J, et al. Baseline characteristics from a phase 3 trial of crenezumab in prodromal to mild Alzheimer's disease (CREAD). *Alzheimers Dement*. 2018;14(7 Suppl):P217.
9. Voyle N, Abi-Saab D, Klein G, Hofmann C, Delmar P, Pross N, et al. The effect of low doses of gantenerumab on amyloid and tau biomarkers in cerebrospinal fluid (CSF) in the Marguerite Road Study. *Alzheimers Dement*. 2018;14(7 Suppl):P240.
10. Klein G, Delmar P, Hofmann C, Adjelkovic M, Abi-Saab D, Milosavljevic-Ristic S, et al. Higher dose gantenerumab leads to significant reduction in amyloid plaque burden - Results for the Marguerite and Scarlet Road open label extension studies. *Neurology*. 2018;90(15 Suppl):S2.005.
11. Alverson WA, Massman PJ, Doody RS. Longitudinal cognitive asymmetry and decline in Alzheimer's disease patients. *J Int Neuropsychol Soc*. 2017;23(Suppl S1):217-8.
12. Margolin RA, Schneider LS, Cutter GR, Breitner JCS, Doody RS, Landreth G, et al. Advancing therapeutics for neuroinflammation in Alzheimer's disease: Clinical development considerations. *Alzheimers Dement*. 2016;12(7 Suppl):P822.
13. Siffert J, Hammond F, Alexander D, Cutler A, D'Amico S, Doody R, et al. PRISM II: Effectiveness of dextromethorphan 20 mg/quinidine 10 mg (Nuedexta®) for treatment of pseudobulbar affect secondary to dementia, stroke, or traumatic brain injury: Combined results of a multicenter open-label study. *Neurology*. 2016;86(Meeting Abstracts 1):P2.225.
14. Viglietta V, O'Gorman J, Williams L, Tian Y, Sandrock A, Doody R, et al. Randomized, double-blind, placebo-controlled studies to evaluate treatment with aducanumab (BIIB037) in patients with early Alzheimer's disease: Phase 3 study design. *Neurology*. 2016;86(Meeting Abstracts 1):S1.003. [Oral Presentation]
15. Lazar E, Woodward M, Amrutkar C, Hagemeyer J, Shah H, Benedict R, et al. Validation of olfactory identification deficit as a biomarker of Alzheimer's disease. Program No. 622.14. 2015 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2015. Online.
16. Doody RS, Cutler AJ, D'Amico S, Shin P, Ledon F, Yonan C, et al. Dextromethorphan/quinidine for treatment of pseudobulbar affect (PBA) in patients with dementia: Comparison of patient-reported ratings to those of caregiver proxies in a 12-week open-label trial (PRISM II). *Alzheimers Dement*. 2015;11(7 Suppl):P471.
17. Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al. Dextromethorphan/quinidine for treatment of pseudobulbar affect (PBA) in patients with dementia: Examination of CNS-LS outcomes in a 12-week open-label trial (PRISM II). *Alzheimers Dement*. 2015;11(7 Suppl):P743.
18. Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al. Dextromethorphan/quinidine for treatment of pseudobulbar affect in patients with dementia: Treatment effects by concomitant antidepressant use in a 12-week open-label trial (PRISM II). *Alzheimers Dement*. 2015;11(7 Suppl):P292. [Platform Presentation]
19. Sabbagh MN, Burstein A, Grimes I, Valcarce C, Doody RS, Sano M, et al. TTP488 path to registration: Leveraging enrichment strategies. *Alzheimers Dement*. 2015;11(7 Suppl):P758.
20. Sabbagh MN, Burstein A, Grimes I, Valcarce C, Rose E, Doody RS, et al. TTP488: From futile to fast track. *Alzheimers Dement*. 2015;11(7 Suppl):P290.
21. Amrutkar C, Woodward M, Shah H, Benedict R, Rajakrishnan S, Doody R, et al. Validation of olfactory deficit as a biomarker of Alzheimer's disease. *Neurology*. 2015;84(Meeting Abstracts 1):P2.170.
22. Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al. PRISM II: An open-label study to assess the safety, tolerability, and effectiveness of dextromethorphan 20 mg/quinidine 10 mg for treatment of pseudobulbar affect secondary to dementia, stroke, or traumatic brain injury: Results from the Alzheimer's disease/dementia cohort. *Neurology*. 2015;84(Meeting Abstracts 1):P7.109.
23. Doody RS, D'Amico S, Cutler AJ, Shin P, Ledon F, Yonan C, et al. WIP safety, tolerability, and effectiveness of dextromethorphan/quinidine for pseudobulbar affect in patients with Alzheimer's disease/dementia: PRISM-II.

- Ann Neurol. 2014;76 Suppl 18: S99-100.
24. Majid T, Chan W, Darby E, Pavlik V, Doody R. Antioxidant biomarkers predict annualized change in MMSE score in MCI and AD patients in the TARCC cohort. *Ann Neurol.* 2014;76 Suppl 18:S94-5.
 25. Grill JD, Raman R, Ernstrom K, Dowsett S, Chen Y-F, Liu-Seifert H, et al. Comparing recruitment among geographic regions in multinational Alzheimer's disease clinical trials. *Alzheimers Dement.* 2014;10(4 Suppl):P852-P853.
 26. Henley DB, Dowsett SA, Chen Y-F, Liu-Seifert H, Grill JD, Doody R, et al. Regional variation in Alzheimer's disease progression in a clinical trial setting. *Alzheimers Dement.* 2014;10(4 Suppl):P821.
 27. Alverson WA, Massman PJ, Grabyan JM, Doody RS. Progression and stability of cognitive asymmetry in a large sample of Alzheimer's disease patients. *J Int Neuropsychol Soc.* 2014;20(Suppl S1):159-60.
 28. Doody R, Cutler A, D'Amico S, Zorowitz R, Alexander D, Hammond F, et al. A study to assess the safety, tolerability, and effectiveness of Nuedexta (dextromethorphan 20 mg/quinidine 10 mg) in the treatment of pseudobulbar affect (PBA) [PRISM II]. *Alzheimers Dement.* 2013;9(4 Suppl):P662.
 29. Szigeti K, Trummer B, Lal D, Yan L, Song L, Doody R. Ordered subset analysis CNV association with Alzheimer's disease AAO phenotypes. *Alzheimers Dement.* 2013;9(4 Suppl):P176-P177.
 30. Biernot J, Darby E, Chan W, Pavlik V, Doody R. Examining anti-dementia drug persistence in Alzheimer's disease (AD) patients. *Neurology.* 2013;80(Meeting Abstracts 1):P07.140.
 31. Grabyan JM, Massman PJ, Alverson W, Doody RS. A simple method for enhancing prediction of longitudinal decline in instrumental activities of daily living in Alzheimer's patients. *J Int Neuropsychol Soc.* 2013;19(Suppl S1):214.
 32. Lowe DA, Balsis S, Miller T, Bengtson JF, Doody RS. Improving predictive validity of the Clinical Dementia Rating Scale for functional outcomes. *J Int Neuropsychol Soc.* 2013;19(Suppl S1):128-9.
 33. Szigeti K, Lal D, Li Y, Doody RS, Yan L. Genome-wide scan for copy number variation association with age at onset of Alzheimer's disease. *Ann Neurol.* 2012;72 Suppl 16:S134-5. [Platform Presentation]
 34. Doody R, Chan W, Pavlik V, Rountree S, Massman P. Premorbid IQ and intrinsic progression rate explain substantial variance in observed progression of Alzheimer's disease (AD) on multiple measures. *Alzheimers Dement.* 2012;8(4 Suppl):P455.
 35. McGee JS, Nguyen A, Darby E, Chan W, Pavlik V, Doody R. Factors influencing time to nursing home placement in persons with probable Alzheimer's disease. *Alzheimers Dement.* 2012;8(4 Suppl):P374.
 36. Rountree S, Chan W, Pavlik V, Doody R. Factors that influence long term care placement in an Alzheimer disease cohort. *Alzheimers Dement.* 2012;8(4 Suppl):P375.
 37. Szigeti K, Li Y, Shaw C, Sheffer I, Sule N, Powell S, et al. Integrated copy number and gene expression analysis detects a CREB1 association with Alzheimer's disease. *Alzheimers Dement.* 2012;8(4 Suppl):P672.
 38. Winblad B, Doody R, Cummings J, Tariot P, Sano M, Aisen P, et al. Donepezil in Alzheimer's disease: Summary and contract of three efficacy trials. *Alzheimers Dement.* 2012;8(4 Suppl):P456.
 39. Grabyan JM, Massman PJ, Porter B, Doody RS. Plasma cortisol does not predict rate of cognitive decline in Alzheimer's patients. *J Int Neuropsychol Soc.* 2012;18(Suppl S1):263.
 40. McGee JS, Darby EJ, Biernot J, Doody RS. Amnesic MCI, sleep disturbance, and cognitive functioning. *J Int Neuropsychol Soc.* 2012;18(Suppl S1):277.
 41. Barber R, O'Bryant S, Reisch J, Doody R, Fairchild T, Adams P, et al. Serum granulocyte colony stimulating factor and Alzheimer's disease. *Alzheimers Dement.* 2011;7(4 Suppl):S313.
 42. Dentino A, Hall J, Barber R, Doody R, Royall D, O'Bryant S. The impact of depression on cognition varies by APOE4 status. *Alzheimers Dement.* 2011;7(4 Suppl):S350.
 43. Doody R, Chan W, Ballantyne C, Pavlik V, Barber R, O'Bryant S, et al. Biomarkers associated with cardiovascular risk in the Texas Alzheimer's Disease Research and Care Consortium (TARCC) Cohort: LpPla2 and homocysteine. *Alzheimers Dement.* 2011;7(4 Suppl):S317-S8.
 44. Doody R, Chan W, Barber R, Ballantyne C, Pavlik V, O'Bryant S, et al. Inflammatory biomarkers in the Texas Alzheimer's Research and Care Consortium (TARCC) Cohort. *Alzheimers Dement.* 2011;7(4 Suppl):S318.
 45. Mielke M, Haughey N, Bandaru VVR, Weinberg D, Zaidi N, Pavlik V, et al. Plasma sphingomyelin is associated with cognitive progression in Alzheimer's disease. *Alzheimers Dement.* 2011;7(4 Suppl):S322-S3.
 46. O'Bryant S, Xiao G, Barber R, Hall J, Doody R, Reisch J, et al. Refinement and expansion of the Texas Alzheimer's research consortium serum-based diagnostic algorithm for Alzheimer's disease. *Alzheimers Dement.* 2011;7(4 Suppl):S325.
 47. O'Bryant S, Xiao G, Robert B, Hall J, Doody R, Reisch J, et al. A serum protein-based algorithm for the detection of Alzheimer's disease. *Alzheimers Dement.* 2011;7(4 Suppl):S674-S5.
 48. Pavlik V, Massman P, Rustveld L, Doody R. Racial/ethnic group differences in the association of APOE 4 genotype and visuospatial test performance in a non-demented sample. *Alzheimers Dement.* 2011;7(4 Suppl):S361.
 49. Rountree S, Chan W, Pavlik V, Darby E, Doody R. Factors that influence survival in Alzheimer's patients. *Alzheimers Dement.* 2011;7(4 Suppl):S513.
 50. Royall DR, Doody R, Barber R, Palmer R, O'Bryant S, Reisch J, et al. The cognitive correlates of functional

- status: a new approach to dementia. *Alzheimers Dement*. 2011;7(4 Suppl):S175.
51. Wilhelmsen K, Chasse S, Griffin N, Diaz-Arrastia R, Barber R, Royall D, et al. Genome-wide association scan replication for biomarker endophenotypes of Alzheimer's disease. *Alzheimers Dement*. 2011;7(4 Suppl):S335-S6.
 52. Xiao G, Barber R, Reisch J, Doody R, Fairchild T, Adams P, et al. Developing and validating of diagnostic algorithm for Alzheimer's disease. *Alzheimers Dement*. 2011;7(4 Suppl):S334-S5.
 53. Doody RS, Ramos H, Faison W, Zou H. Efficacy and safety of donepezil 23 mg/day in patients with moderate-to-severe Alzheimer's disease with concomitant memantine use. *Neurology*. 2011;76(Suppl 4):A619-20.
 54. Pavlik V, Massman P, Ballantyne C, Barber R, Doody RS. Differences in the association of peripheral insulin and cognitive function in non-diabetic ad cases and normal controls. *Neurology*. 2011;76(Suppl 4):A122.
 55. Havins W, Harika L, Massman PJ, Doody RS. Differential recall of nouns and verbs in patients with probable Alzheimer's disease (AD). *J Int Neuropsychol Soc*. 2011;17(Suppl S1):75.
 56. Havins WN, Agbayani KA, Massman PJ, Doody RS. Cognitive reserve as a moderator for the relationship between depression and cognitive functioning in Alzheimer's disease. *J Int Neuropsychol Soc*. 2011;17(Suppl S1):75.
 57. Massman PJ, Burrows C, Hall J, Doody RS. Cortisol levels in Alzheimer's patients are related to premorbid functioning and rate of progression. *J Int Neuropsychol Soc*. 2011;17(Suppl S1):77.
 58. Barber R, Xiao G, O'Bryant S, Saunders J, Reisch J, Doody R, et al. An inflammatory endophenotype of Alzheimer's disease. *Alzheimers Dement*. 2010;6(4 Suppl):S530.
 59. Chan M, Pavlik VN, Chan W, Darby E, Khaleeq A, Doody RS. Presence of cardiovascular disease is associated with slower cognitive decline in Alzheimer's disease in the absence of cerebrovascular pathology. *Alzheimers Dement*. 2010;6(4 Suppl):S460.
 60. Diaz-Arrastia R, Xiao G, Reisch J, Barber R, Doody R, Fairchild T, et al. A serum protein-based diagnostic algorithm for Alzheimer's disease. *Alzheimers Dement*. 2010;6(4 Suppl):S130.
 61. Doody RS, Tariot P, Cummings J, Winblad B, Selby B, Langenberg A, et al. Results from CONNECTION: A global, Phase 3 double-blind, placebo-controlled confirmatory trial of dimebon (latrepirdine) in patients with mild-to-moderate Alzheimer's disease. *Alzheimers Dement*. 2010;6(4 Suppl):S147.
 62. Huebinger RM, Wilhelmsen K, Diaz-Arrastia R, Chasse S, O'Bryant SE, Doody R, et al. Association of genetic variation in the electron transport chain and Alzheimer's disease. *Alzheimers Dement*. 2010;6(4 Suppl):S195-S196.
 63. Wilhelmsen KC, Chasse SA, Gizer IR, Cameron NG, Ellis JW, Diaz-Arrastia R, et al. Genome-wide association scan for biomarker endophenotypes of Alzheimer's disease. *Alzheimers Dement*. 2010;6(4 Suppl):S129.
 64. Bengtsson J, Balsis S, Geraci L, Massman P, Doody R. How well does the ADAS-cog measure the spectrum of Alzheimer's disease severity? An item response theory analysis. *Neurology*. 2009;72(11 Suppl 3):A247.
 65. Doody R, Chan W, Pavlik V, Massman P, Darby E, Rountree S, et al. Age at onset and pre-morbid IQ influence early progression rates in AD. *Neurology*. 2009;72(11 Suppl 3):A478.
 66. Massman P, Doody RS. Significance of the apolipoprotein E 2 allele in Alzheimer's patients' memory functioning. *J Int Neuropsychol Soc*. 2009;15(Suppl S1):202.
 67. Cummings J, Doody RS, Gavrilova S, Sano M, Aisen P, Seely L, et al. Eighteen-month data from an open-label extension of a one-year controlled trial of dimebon in patients with mild-to-moderate Alzheimer's disease. *Alzheimer's & Dementia*. 2008;4(4 Suppl):T770-1.
 68. Doody RS, Ferris SH, Salloway S, Meuser TM, Murthy AK, Li MC, et al. Interrater reliability between expert and nonexpert physicians in the assessment of amnesic MCI in the community setting. *Alzheimer's & Dementia*. 2008;4(4 Suppl):T263.
 69. Doody RS, Gavrilova S, Thomas R, Aisen P, Bachurin S, Seely L, et al. Dimebon improves cognition, function, and behavior in mild and moderate Alzheimer's disease: Results by severity of a one-year, double-blind, placebo-controlled study. *Alzheimer's & Dementia*. 2008;4(4 Suppl):T771.
 70. Murthy AK, Schuff N, Suhy J, Doody RS, Goldman R. The effects of donepezil on Alzheimer's disease progression monitored by MRI. *Alzheimer's & Dementia*. 2008;4(4 Suppl):T55.
 71. Rountree S, Pavlik V, Chan W, Doody RS. Persistent antedementia drug treatment and survival in an Alzheimer's disease (AD) cohort. *Alzheimer's & Dementia*. 2008;4(4 Suppl):T698-9.
 72. Sparks L, Kivipelto M, Doody RS, Waters D, Jones RW, Feldman H, et al. The Atorvastatin/Donepezil in Alzheimer's Disease Study (LEADe): Effect of atorvastatin on Alzheimer's disease progression by APOE4 genotype. Presented at the 2008 International Conference on Alzheimer's Disease (ICAD), Chicago, Ill. (July 26-31, 2008).
 73. Doody RS, Ferris S, Salloway S, Meuser T, Murthy A, Li MC, et al. Inter-rater reliability between expert and nonexpert physicians in the diagnosis of amnesic MCI in the community setting. *Neurology*. 2008;70(11 Suppl 1):A147.
 74. Doody RS, Gavrilova S, Aisen P, Hirmand M, Sano M. Dimebon improves patient function and decreases caregiver assistance time in Alzheimer's disease: One-year clinical trial results. *Neurology*. 2008;70(11 Suppl 1):A98.

75. Ferris S, Doody R, Gavrilova S, Sano M, Aisen P, Seely L. Dimebon improves memory, orientation, language, and praxis in patients with mild to moderate Alzheimer's disease: Results of a one-year placebo-controlled study. *Neurology*. 2008;70(11 Suppl 1):A393-4.
76. Pavlik VN, Doody RS, Rountree SD, Darby EJ. Vitamin E use is associated with improved survival in an AD cohort. *Neurology*. 2008;70(11 Suppl 1):A146.
77. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Gulley A, et al. Exposure to anti-dementia drugs slows clinical progression of Alzheimer's disease (AD). *Ann Neurol*. 2007;62 Suppl 11:S55.
78. Doody R, Garrilova S, Sano M, Thomas R, Aisen P, Bachurin S, et al. Results of a one-year randomized, placebo-controlled trial of dimebon for the treatment of mild to moderate Alzheimer's disease. *Alzheimers Dement*. 2007;3(3 Suppl):S199-200.
79. Jones R, Doody R, Sparks DL, Feldman H, Kivipelto M, Breazna A, et al. Lipitor's effect in Alzheimer's dementia (LEADe) study: Baseline characteristics. *Alzheimers Dement*. 2007;3(3 Suppl):S192-3.
80. Rountree SD, Pavlik VN, Chan W, Darby EJ, Doody RS. Clinical factors associated with the preprogression rate (PPR) in Alzheimer's disease (AD). *Alzheimers Dement*. 2007;3(3 Suppl):S130.
81. Senanarong V, Hamphadungkit K, Pongvarin N, Cummings J, Doody R. The dementia and disability in Thai elderly project: Prevalence of mild cognitive impairment with one-year follow-up and the prevalence of dementia in community-dwelling Thai elderly. *Alzheimers Dement*. 2007;3(3 Suppl):S178.
82. Doody R, Gavrilova S, Sano M, Thomas R, Aisen P, Seely L, et al. Dimebon improves cognition, function, and behavior in patients with mild- moderate Alzheimer's disease: Results of a randomized, double-blind, placebo-controlled study. *Neurology*. 2007;68(12 Suppl 1):A353.
83. Feldman H, Sparks L, Doody R, Kivipelto M, Jones R, Sovel M, et al. Design and baseline data for a study of Lipitor's effect in Alzheimer's disease (LEADe). *Neurodegener Dis*. 2007;4 Suppl 1:333.
84. Doody R, Pavlik V, Massman P, Rountree S, Waring S, Darby E, et al. Predicting progression and survival in Alzheimer's disease. *Alzheimer's & Dementia*. 2006;2(3 Suppl):S83.
85. Park KW, Pavlik VN, Rountree SD, Darby EJ, Doody RS. Is functional decline necessary for a diagnosis of Alzheimer's disease? *Alzheimer's & Dementia*. 2006;2(3 Suppl):S263.
86. Rountree SD, Waring SC, Chan W, Darby EJ, Doody RS. Clinically presenting mild cognitive impairment (MCI): Variable presentations and their outcomes. *Alzheimer's & Dementia*. 2006;2(3 Suppl):S269.
87. Waring SC, Paranilam JM, Doody RS, Darby EJ, Massman PJ, Chan W. Preprogression rate, cardiovascular comorbidity, and survival in Alzheimer's disease. *Alzheimer's & Dementia*. 2006;2(3 Suppl):S159.
88. Doody R, Pavlik V, Massman P, Rountree S, Darby E, Chan W. Predicting progression of Alzheimer's disease. *Neurology*. 2006;66(5 Suppl 2):A347.
89. Pavlik VN, Hyman DJ, Balasubramanyam A, Doody R. Association between cognitive function and metabolic control parameters in treated patients with type 2 diabetes. *Circulation*. 2006;113(8):e342.
90. Acharya D, Massman P, Doody R. Neuropsychological and demographic correlates of apraxia in a large cohort of Alzheimer's patients. *Int J Neurosci*. 2006;12(Suppl S1):47.
91. Bengel J, Massman P, Jenkins R, Thornton G, Doody R. Phonemic cued performance on the Boston Naming Test: Longitudinal change and its correlates in Alzheimer's disease. *Int J Neurosci*. 2006;12(Suppl S1):55.
92. Jenkins R, Massman P, Bengel J, Thornton G, Doody R. Naming improvement with phonemic cues: Which Alzheimer's patients benefit most? *Int J Neurosci*. 2006;12(Suppl S1):51.
93. Thornton G, Massman P, Bengel J, Jenkins R, Doody R. Category-letter fluency discrepancies in healthy older adults: Normative data and reliability. *Int J Neurosci*. 2006;12(Suppl S1):192.
94. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM. Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease. *Ann Neurol*. 2005;58 Suppl 9:S49-50.
95. Doody RS, Tariot PN, Pfeiffer E, Olin JT, Graham SM, Bell JM. Meta-analysis of 6-month memantine clinical trials in Alzheimer's disease. *Alzheimers Dement*. 2005;1(1 Suppl):S67.
96. Thal LJ, Thomas RG, Grundman M, Bennett DA, Doody RS, Ferris SH, et al. Donepezil and vitamin E in the progression of mild cognitive impairment to Alzheimer's disease: A hazard-ratio analysis. *Alzheimers Dement*. 2005;1(1 Suppl):S93.
97. Issa A, Rountree S, Waring S, Yeh S, Doody RS. Mild cognitive impairment types and their outcomes. *Neurology*. 2005;64(6 Suppl 1):A168.
98. Massman P, Doody RS. ADAS-Cog change rates in MMSE Strata relevant to clinical trials. *Neurology*. 2005;64(6 Suppl 1):A70.
99. Pavlik V, Doody RS, Massman P, Chan W, Yeh S. Relationship of premorbid IQ and education to progression of Alzheimer's disease. *Neurology*. 2005;64(6 Suppl 1):A317.
100. Schindler R, Corey-Bloom J, Doody R, Zhang R, Leni JR, Li H. Donepezil is safe and well-tolerated in AD patients at doses of up to 20 mg/day. *Eur J Neurol*. 2004;11(Suppl 2):44.
101. Wirth Y, Doody RS, Schmitt FA, Mobius HJ, Stoffler A. Functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease. *Eur J Neurol*. 2004;11(Suppl 2):193.
102. Doody R, Pratt R, Posner H, Kumar D. Vascular dementia patients who receive donepezil treatment for 12 to 18 months maintain cognitive benefits. *Neurobiol Aging*. 2004;25 Suppl 2:S469-70.

103. Massman P, Doody R. Longitudinal analysis of the Alzheimer's Disease assessment scale in a large cohort of probable AD patients. *Neurobiol Aging*. 2004;25 Suppl 2:S120.
104. Tariot P, Doody R, Peskind E, Winblad B, Reisberg B, Stoffler A, et al. Memantine treatment for mild to severe Alzheimer's disease: Clinical trials summary. *Neurobiol Aging*. 2004;25 Suppl 2:S99-100.
105. Wirth Y, Doody RS, Schmitt FA, Mobius HJ. Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease. *Neurobiol Aging*. 2004;25 Suppl 2:S205.
106. Wirth Y, Doody R, Schmitt F, Mobius HJ, Stoffler A. Memantine treatment is beneficial for functional capacities of patients with moderate to severe Alzheimer's disease. *Int J Neuropsychopharmacol*. 2004;7 Suppl 2:S207.
107. Doody RS, Pratt RD, Perdomo CA, the Donepezil 307 and 308 VaD Study Groups. Donepezil-treated patients demonstrate global benefits on the Clinician's Interview-Based Impression of Change-Plus version: A comparison of Alzheimer's disease versus vascular dementia. *Neurology*. 2003;60(5 Suppl 1):A412.
108. Ferris SH, Schmitt FA, Doody RS, Moebius H-J, Stoeffler A, Reisberg BJ. Long-term treatment with the NMDA antagonist, memantine: Results of a 24-week, open-label extension study in moderate to severe Alzheimer's disease. *Neurology*. 2003;60(5 Suppl 1):A414.
109. Clark C, Eubank D, Peskind E, Galasko D, Morris J, McKeel D, et al. How well do cerebral spinal fluid tau levels discriminate autopsy confirmed Alzheimer's disease from other dementia diagnoses? *Neurobiol Aging*. 2002;23(1 Suppl):S274.
110. Doody RS. Pathogenesis and treatment strategies for selected therapies under development. *Neurobiol Aging*. 2002;23(1 Suppl):S144.
111. Reisberg B, Mobius H, Stoffler A, Schmitt F, Doody R, Ferris S. Long term treatment with the NMDA antagonist memantine: results of a 24-week, open label extension study in moderately severe to severe Alzheimer's disease. *Neurobiol Aging*. 2002;23(1 Suppl):S555.
112. Pavlik VN, Hyman DJ, Doody R. Cognitive function and cardiovascular risk factors in adults 30-59 years old (NHANES III). *Am J Epidemiol*. 2002;155(Suppl):S24.
113. Waring S, Doody RS. Survival in patients with dementia from a large multi ethnic population. *Neuroepidemiology*. 2002;21:211.
114. Davis R, Atchison T, Massman P, Doody R. Growth curve analysis of decline in instrumental activities of daily living in AD patients. *J Int Neuropsychol Soc*. 2002;8:266.
115. Davis R, Massman P, Doody R. Measurement invariance of the WAIS-R in AD among patients at higher versus lower levels of dementia severity. *J Int Neuropsychol Soc*. 2002;8:158.
116. Davis R, Massman P, Doody R. WAIS-R factor structure in AD: Comparison of alternative models and assessment of generalizability. *J Int Neuropsychol Soc*. 2002;8:265.
117. Doody RS, Kershaw P. The cognitive benefits of galantamine are sustained for at least 24 months: Results of a long-term extension trial in Alzheimer's disease. *Neurology*. 2001;56(8 Suppl 3):A456.
118. Waring S, Doody RS. Racial differences among patients with Alzheimer's disease from a large multi ethnic population. *Neuroepidemiology*. 2001;20:118.
119. Doody RS. Cholinesterase inhibitors: Benefits and limitations. *Neurobiol Aging*. 2000;21(1 Suppl):S8.
120. Mohs R, Doody R, Morris J, Ieni J, Perdomo C, Pratt R. Donepezil preserves activities of daily living in Alzheimer's disease patients: Results from a 1-year placebo-controlled functional survival study. *Neurology*. 2000;54(Suppl 3):A415.
121. Sumaira R, Doody R, Lai EC. Profoundly advanced Alzheimer's disease: Patient characteristics, functional status, disease progression, and care burden. *Neurology*. 2000;54(Suppl 3):A417.
122. Doody R, Geldmacher DS, Pratt RD, Perdomo CA. Uninterrupted long-term donepezil treatment results in optimal efficacy with retained safety. *Consult Pharm*. 1999;14(10):1142.
123. Mohs R, Doody R, Morris J, Ieni J, Rogers S, Perdomo C, et al. Donepezil preserves functional status in Alzheimer's disease patients: Results from a 1-year placebo-controlled attrition study. *Eur Neuropsychopharmacol*. 1999;9 Suppl 5:S328.
124. Doody RS, Geldmacher DS, Pratt RD, Perdomo CA. Optimal donepezil efficacy in Alzheimer's disease is dependent on continued administration. *J Neurol*. 1999;246 Suppl 1:I52.
125. Azher S, Doody RS, Haykal H, Dunn JK, Liao T-Y. Does ApoE4 correlate with MRI changes in Alzheimer's disease? *Neurology*. 1999;52(Suppl 2):A366.
126. Doody RS, Pratt R, Perdomo C. Clinical benefits of donepezil: Results from a long-term phase III extension trial. *Neurology*. 1999;52(Suppl 2):A174.
127. Petit H, Doody RS, Pratt R. Donepezil improves cognition and global function in Alzheimer's disease: Results from U.S. and multinational phase III clinical trials. *Eur Neuropsychopharmacol*. 1998;8 Suppl 2:S274.
128. Doody RS, Clark C, Farlow M, Foster N, Gonzales N, Liao J, et al. Chronic donepezil treatment is associated with slowed cognitive decline in Alzheimer's disease patients. *Neurobiol Aging*. 1998;19(Suppl 45):S303.
129. Katakami M, Doody RS, Liao J, Sims J. The presence of APO E4 does not influence rate of decline in Alzheimer's disease. *Neurobiol Aging*. 1998;19(Suppl 45):S137.

130. Doody RS. Current therapeutic standards in the treatment of Alzheimer's disease. Proceedings of the Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. 1998:32.
131. Rogers S, Mohs R, Friedhoff L, Doody RS. Research outcome measures in Alzheimer's disease: Statistical significance, effect size and responder analysis - How do they translate to clinical relevance? Proceedings of the Fifth International Geneva/Springfield Symposium on Advances in Alzheimer Therapy. 1998:32.
132. Quinn JF, Benson DF, Clark C, Doody RS, Jagust W, Knopman D, et al. Outcome measures in dementia trials-video CIBIC validity and reliability. *Neurology*. 1997;48(3):A233-A234.
133. Rogers SL, Doody RS, Mohs RC, Friedhoff LT. Donepezil HCl (E2020) improves cognitive and global function in patients with mild and moderately severe Alzheimer's disease: Results of a 15-week phase III study. Presented at the American College of Neuropsychopharmacology (ACNP), 35th Annual Meeting in San Juan, Puerto Rico (Dec. 9-13, 1996).
134. Kashani A, Doody RS, Wayner MJ, Phelix CF. Prevalence of uncontrolled hypertension in a population of Alzheimer's patients. Presented at the International Behavioral Neuroscience Society (IBSN), 5th Annual Meeting in Cancun, Mexico (May 2-5, 1996).
135. Grundman M, Petersen R, Morris J, Ferris S, Sano M, Farlow M, et al. Rate of dementia of the Alzheimer's type (DAT) in subjects with mild cognitive impairment. *Neurology*. 1996;46(2):A403.
136. Rogers S, Doody RS, Mohs R, Friedhoff L. E-2020 Produces both clinical global and cognitive test improvement in patients with mild to moderately severe Alzheimer's disease (AD): Results of a 30-week phase III trial. *Neurology*. 1996;46(2):A217.
137. Sabbagh N, Smith RG, Lynn P, Doody RS, Appel SH, Killian JH. Pharmacologic evidence for autonomic sudomotor dysfunction in patients with Alzheimer's disease. *Neurology*. 1996;46(2):A162.
138. Olin J, Clark C, Doody RS, Schmitt F, Ferris S, Morris J, et al. Reliability and validity of a new clinical global rating scale for Alzheimer's clinical trials. *Int J Neurosci*. 1996;2:4.
139. Olin J, Schneider L, Clark C, Doody RS, Ferris S, Morris J, et al. A new clinical global rating scale for Alzheimer's clinical trials. *Gerontologist*. 1995;35(2):63.
140. Doody RS, Young R, Lynn P, Cooke N, Rosenfield JE. Estrogen and psychomotor performance. *J Neuropsychiatry Clin Neurosci*. 1995;7(3):410.
141. Doody RS, Lynn P, Massman PJ. A calculated measure to predict rate of progression in Alzheimer's disease. *Neurology*. 1995;45(4 Suppl 4):A195.
142. Massman PJ, Doody RS. Sex differences involving naming in Alzheimer's disease: Stronger relationships with left hemisphere functioning in men. *Int J Neurosci*. 1995;145.
143. Doody RS, Massman PJ, Nance ML. Psychometric profiles of Alzheimer's disease (AD) with/without white matter changes compared to subcortical ischemic vascular dementia (IVD). *Neurology*. 1994;44(4 Suppl 2):A196.
144. Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological distinctions between cortico-basal ganglionic degeneration (CBGD) and Alzheimer's disease with extrapyramidal signs. *Neurology*. 1994;44(4 Suppl 2):A194.
145. Massman PJ, Kreiter KT, Jankovic J, Doody RS. Neuropsychological differentiation of corticobasal degeneration from Alzheimer's disease. *Int J Neurosci*. 1994;43.
146. Doody RS, Massman P. Dysfluency in the speech of AD patients. *Ann Neurol*. 1993;34(2):249.
147. Doody RS, Welsh K. Literacy and cognition in northern Thailand. *Ann Neurol*. 1993;34(2):249.
148. Dunn W, Doody RS, Gopnik M, Ashizawa T. Simulation analysis of a large British pedigree segregating a newly characterized autosomal dominant language disorder: Familial developmental dysphasia. *Am J Hum Genet*. 1993;53(Suppl):A1692.
149. Kotrla K, Chacko R, Jhingran S, Doody RS. Neuroimaging findings and clinical variables associated with psychosis in Alzheimer's disease. Presented at the American Psychiatric Association (APA), 146th Annual Meeting in San Francisco, Calif. (May 22-27, 1993).
150. Massman P, Doody RS. Correlates of asymmetric motor speed in Alzheimer's disease. *J Clin Exp Neuropsychol*. 1993;15:31.
151. Massman P, Doody RS. Neuropsychological correlates of apraxia in Alzheimer's disease patients. *Arch Clin Neuropsychol*. 1992;8:249-50.
152. Doody RS. Positioning: Neurology and anthropology enabling practices. Presented at the American Anthropological Association (AAA), 90th Annual Meeting in Chicago, Ill. (Nov. 20-24, 1991).
153. Doody RS, Strittmatter WJ, Jhingran S. Single photon emission computerized tomography (SPECT) in Alzheimer's disease and multiple-infarct dementia. *Ann Neurol*. 1991;30(2):249-50.
154. Feher E, Mahurin R, Doody RS, Cooke N, Simms J, Pirozzolo F. Establishing the limits of the mini-mental state: MMS "subtests" versus a full neuropsychological battery. *Ann Neurol*. 1991;30(2):285-6.
155. Mahurin R, Feher E, Doody RS, Inbody S. Positive and negative psychiatric symptoms in Alzheimer's disease. *Ann Neurol*. 1991;30(2):239.
156. Doody RS, Jankovic J. The alien hand and related signs. *Neurology*. 1991;41(3 Suppl 1).
157. Doody RS. Sense and nonsense: Dissemination and empiricism in practice. Presented at the American

- Anthropological Association (AAA), 89th Annual Meeting in New Orleans, La. (Nov. 27 - Dec. 2, 1990).
158. Doody RS, Hrachovy RA. Recurrent posterior-type aphasia associated with a seizure focus. *Electroencephalogr Clin Neurophysiol.* 1991;79:28.
 159. Feher E, Doody RS, Whitehead J, Priozzolo F. Progressive nonfluent aphasia. *Neurology.* 1990;40(4 Suppl 1).
 160. Ornish DM, Scherwitz LW, Doody RS, et al. Effects of stress management and dietary changes in treating ischemic heart disease. Presented at the American College of Cardiology (ACC), 3rd Annual Scientific Session in Atlanta, Ga. (April 25-29, 1982).